Atorvastatin Inhibits High-Fat Diet-Induced Lipid Metabolism Disorders in Rats by Inhibiting Bacteroides Reduction and Improving Metabolism

Huimin Li\(^1,2,*\), Shue Wang\(^3,*\), Shuai Wang\(^4\), Hai Yu\(^1\), Wenhao Yu\(^5,6\), Xiaomin Ma\(^3\), Xiaodong He\(^1,6\)

\(^1\)Department of Physical and Chemical Inspection, School of Public Health, Cheeoloo College of Medicine, Shandong University, Jinan, Shandong, 250012, People’s Republic of China; \(^2\)National Human Genetic Resources Center; National Research Institute for Health and Family Planning; Chinese Academy of Medical Sciences & Peking Union Medical College, Beijing, People’s Republic of China; \(^3\)Preventive Medicine Experimental Teaching Center; School of Public Health, Cheeoloo College of Medicine, Shandong University, Jinan, Shandong, 250012, People’s Republic of China; \(^4\)Department of Toxicology and Nutrition, School of Public Health, Cheeoloo College of Medicine, Shandong University, Jinan, Shandong, 250012, People’s Republic of China; \(^5\)Department of Biostatistics, School of Public Health, Cheeoloo College of Medicine, Shandong University, Jinan, Shandong, 250012, People’s Republic of China; \(^6\)Institute for Medical Dataology, Shandong University, National Institute of Health Data Science of China, Jinan, Shandong, 250012, People’s Republic of China

*These authors contributed equally to this work

Correspondence: Xiaodong He, Tel/Fax +86 531 88382554, Email xiaodong.he@sdu.edu.cn

Purpose: The prevalence of hyperlipidemia and related illnesses is on its rise, and atorvastatin is the frequently used hypolipidemic agent. However, there is still uncertainty about the mechanisms, especially the relationship between the lipid-lowering effect, intestinal microbiome, and metabolic profiles. We aim to intensively explain the mechanism of the hypolipidemic effect of atorvastatin through multi-omics perspective of intestinal microbiome and metabolomics.

Methods: Multi-omics methods play an increasingly important role in the analysis of intestinal triggers and evaluation of metabolic disorders such as obesity, hyperlipidemia, and diabetes. Therefore, we were prompted to explore intestinal triggers, underlying biomarkers, and potential intervention targets of atorvastatin in the treatment of dyslipidemia through multi-omics. To achieve this, SPF Wistar rats were fed a high-fat diet or normal diet for 8 weeks. Atorvastatin was then administered to high-fat diet-fed rats.

Results: By altering intestinal microbiome, a high-fat diet can affect feces and plasma metabolic profiles. Treatment with atorvastatin possibly increases the abundance of Bacteroides, thereby improving “propanoate metabolism” and “glycine, serine and threonine metabolism” in feces and plasma, and contributing to blood lipid reduction.

Conclusion: Our study elucidated the intestinal triggers and metabolites of high-fat diet-induced dyslipidemia from the perspective of intestinal microbiome and metabolism. It equally identified potential intervention targets of atorvastatin. This further explains the mechanism of the hypolipidemic effect of atorvastatin from a multi-omics perspective.

Keywords: hyperlipidemia, 16S rRNA sequencing, intestinal microbiome, metabolomics, atorvastatin calcium trihydrate

Introduction

Long-term intake of a high-fat diet (HFD) can cause hyperlipidemia, leading to a gradual increase in its incidence. Hyperlipidemia can result in cardiovascular and cerebrovascular diseases, thereby posing a major threat to human health. Therefore, the prompt control of abnormal blood lipid elevations will significantly lower the incidence of cardiovascular and cerebrovascular diseases. Hyperlipidemia is a chronic condition with an insidious onset, thus requiring daily medication. Statins are a class of medications frequently used to reduce blood lipid levels by inhibiting 3-hydroxy-3-methylglutaryl-CoA reductase. Atorvastatin can also reduce LDL-Cholesterol levels and plasma cholesterol by inhibiting the major histocompatibility complex II (MHC II) on antigen-presenting cells stimulated by interferon-γ. Although the modes of action of atorvastatin have been intensively investigated, there is still uncertainty...
about the mechanisms, especially the relationship between the lipid-lowering effect, intestinal microbiome, and metabolic profiles.

Increasing evidence suggest a close relationship between HFD, intestinal microbiome and metabolic profiles. Consuming a HFD for an extended period of time alters the intestinal microbiome,11 resulting in obesity, atherosclerosis, and other disorders.12,13 Intestinal microbiome is closely related to lipid metabolism.14,15 For example, Bacteroides has bile salt hydrolase activity that can improve cholesterol metabolism.16–18 This plays an important role in hyperlipidemia.19 Long-term intake of an HFD can also affect metabolites.20 For example, an HFD can reduce 2-hydroxybutyric acid involved in “propanoate metabolism” in feces and plasma.21 Fecal metabolites are strongly associated with the activity of intestinal microbiome, whereas plasma metabolomics characterizes all small metabolites in plasma, and is closely related to the overall physiology of the organism.22 Metabolomics are closely related to lipid metabolism. For example, “propanoate metabolism” is critical for the tricarboxylic acid cycle, and disorders in propanoate metabolism can affect energy production.23 Glycine, which is involved in “glycine, serine and threonine metabolism”, can promote lipid metabolism.24 We sought to identify potential targets and elucidate the hypolipidemic mechanism of atorvastatin calcium trihydrate through a combined analysis of 16s rRNA sequencing, fecal metabolomics, and plasma metabolomics. Some authors attempted to explain this mechanism. The combined analysis of 16s rRNA sequencing and serum cholesterol showed that HFD affects cholesterol levels by changing the intestinal microbiome. Changes in the microbiome have been linked to atorvastatin treatment in an HFD-induced hypercholesterolemia rat model.9 Thus, the mechanism of action of atorvastatin was studied by changes in the intestinal microbiome or by analyzing plasma metabolites.25

We used an HFD-induced rat model to assess the effect of atorvastatin. We performed the following laboratory investigations: blood biochemistry, liver function tests, and intestinal microbiome analysis through 16S rRNA sequencing. Fecal and plasma metabolomics were then performed using a triple quadrupole-linear ion trap combined with a SCIEX QTRAP® 6500+ mass spectrometer in the multiple-reaction monitoring mode. In addition, we analyzed and interpreted specific intestinal microbiome, fecal and plasma metabolites to understand the mechanism of high-fat diet-induced intestinal microbiome and metabolic disturbances, as well as the potential mechanism of atorvastatin. We found that an HFD altered the intestinal microbiome and atorvastatin reduced blood lipid levels by enhancing the intestinal microbiome and metabolic pathways.

Materials and Methods

Animals and Groups

We used 30 male SPF Wistar rats, weighing 200–220 g for this study. They were purchased from Jinan Pengyue Experimental Animal Breeding Co., Ltd., Jinan, China. Furthermore, they were housed in an experimental environment with a relative humidity of approximately 50% and temperature of approximately 22 °C. After the animals were fed adaptively, they were randomly divided into two groups. There were 20 male Wistar rats in the model group and 10 in the control group. The control group received a maintenance feed while the model group received HFD. Maintenance feed contained the following ingredients: crude protein: ≥ 18%, crude fat ≥ 4%, crude fiber ≤ 5%, crude ash ≤ 8%, moisture ≤ 10%, calcium 1.0–1.8%, total phosphorus 0.6–1.2%, total energy 3.40 kCal/g, energy supply ratio: protein 23.07%, fat 11.85%, carbohydrate 65.08%. The feed was provided by Keao Xieli (Beijing) Feed Co., Ltd. The HFD contained the following ingredients: crude protein: 12.7%, crude fat 18.9%, crude fiber 3.8%, crude ash 4.0%, moisture 9.2%, calcium 0.82%, total phosphorus 0.69%, nitrogen-free extract 53.1%, total energy 4.34 kCal/g, energy supply ratio: protein 11.7%, fat 39.3%, carbohydrate 49%. The feed is provided by Xiao Shu You Tai (Beijing) Biotechnology Co., Ltd. After three weeks of feeding, the high-fat diet rats were randomly divided into two subgroups; 10 were included into the model group (HFD) while the other 10 were considered as the drug intervention group (HFD+A). The control group (Control) received an equal volume of corn oil by gavage and maintenance feed; the model group (HFD) was given an equal volume of corn oil by gavage and HFD; and the drug treatment group (HFD + A) was given HFD and atorvastatin calcium trihydrate 0.1667 mg/kg.bw. Atorvastatin was administered by gavage once every morning for five weeks. The rats were euthanized with 5% chloral hydrate and 12.5% urethane (mixed 1:1), and blood was collected from the
abdominal aorta after 5 weeks of intervention. Total cholesterol (TC), triglyceride (TG), high-density lipoprotein cholesterol (HDL-C), low-density lipoprotein cholesterol (LDL-C), alanine transaminase (ALT), aspartate transaminase (AST), liver coefficients, and liver pathology were measured in all three groups. All animals were grossly examined, and liver tissue was weighed, with the relative weight (organ/body ratio) calculated. Liver lobes were immersed in 10% formalin solution for fixation, dehydrated, embedded, sliced, and stained with hematoxylin-eosin (HE). The histomorphological and pathological changes in the liver were observed under a light microscope. Data were subjected to the Shapiro–Wilks test to determine their distribution. SPSS version 26 was used for statistical analysis. The data were normally distributed. So, TC, TG, HDL-C, LDL-C, ALT, AST, and liver coefficients were analyzed through the one-way ANOVA. We used GraphPad Prism 8 to present comparisons between the groups. This experiment was approved by the Shandong University Preventive Medicine Animal Experiment Ethics Committee (protocol code LL20200303), and the study protocols adhered to the Ethics and Welfare requirements of the National Institutes of Health (NIH).

**16S rRNA Sequencing and Analysis of Intestinal Microbiome**

After the experiment, the rats were moved and their feces were placed in a 1-mL sterile EP tube and kept at −80 °C as soon as possible until the intestinal microbiome was subjected to 16S rRNA sequencing. Cetyl trimethylammonium bromide (CTAB) method was used to extract whole-genome DNA and then barcode-specific primers 515F and 806R was used to amplify 16S rRNA genes in the V4 region. Subsequently, a PCR was performed. Furthermore, an equal volume of 1X loading buffer (containing SYB green) with the PCR products was mixed, and an electrophoresis on a 2% agarose gel was performed. The Qiagen Gel Extraction Kit was used to purify the PCR products after isocratic mixing. The TruSeq® DNA PCR-free Sample Preparation Kit (Illumina, San Diego, CA, USA) was used to generate sequencing libraries and sequenced them on the Illumina NovaSeq platform to generate 250 bp paired-end reads.

To obtain high-quality clean tags, quality control was carried out in accordance with QIIME (version 1.9.1) and the raw tags were filtered. After the tags were compared with the Silva138, chimeric sequences were detected and removed using the UCHIME algorithm. The Uparse software (Uparse v7.0.1001) was used to sequence valid tags. For effective tags, OTU clustering was performed with 97% consistency. The Silva database was equally used to annotate the classification between the sequences. According to the species’ annotation results, the top 10 most abundant species at the phylum level in each group were selected to generate a column chart of the relative abundant number of species. After normalizing the OTU level, alpha diversity, beta diversity, Linear discriminant analysis (LDA) effect size (LEfSe), and Tax4Fun function predictions were analyzed. Alpha diversity included rarefaction curves, rank abundance, and species accumulation boxplots. Beta diversity analysis included PCA, which was used to show whether the community compositions of the three groups were similar. Lefse analysis compared multiple groups to identify species with significant differences in abundance. We predicted the impact of the intestinal microbiome on metabolic pathways using iPath visualization. After calculation with QIIME (version 1.9.1), we used the R-software (version 2.15.3) to display the analysis of sample complexity. Raw data for high-throughput sequencing supporting the findings of this study are publicly available at [https://www.ncbi.nlm.nih.gov/sra](https://www.ncbi.nlm.nih.gov/sra) (ref: PRJNA804702).

**Fecal Metabolomics and Plasma Metabolomics**

After the metabolites were extracted, they were quantitatively analyzed by product ions (Q3) and qualitatively analyzed by parent ion (Q1), daughter ion (Q3), retention time (RT), declustering potential (DP), and collision energy (CE). SCIXE OS Version 1.4 was used to open the mass spectrum file, and chromatographic peak integration and correction were carried out. The metabolites were interpreted using the KEGG database ([http://www.genome.jp/kegg/](http://www.genome.jp/kegg/)), HMDB database ([http://www.hmdb.ca/](http://www.hmdb.ca/)), and Lipid maps database ([http://www.lipidmaps.org/](http://www.lipidmaps.org/)). We carried out quality control using a quality control sample overlap diagram and correlation analysis. After data conversion using metaX, we conducted principal component analysis (PCA) and partial least squares discrimination analysis (PLS-DA), then get the variable importance in the projection (VIP) value of each metabolite. The statistical significance (p value) of each metabolite and fold change (FC) value between the control group and HFD group, as well as HFD group and HFD+A group was calculated by applying the student’s unpaired t-test. The default criteria for screening differential metabolites were VIP > 1, P < 0.05, and FC > 1.2, or VIP > 1, P < 0.05, and FC < 0.833. Ipath was used to analyze whether the
intestinal microbiome is related to metabolic pathways. Volcano plots were drawn using ggplot2 in the R-language, thereby screening the metabolites of interest between the control group and the HFD, HFD and HFD + A groups. The bubble diagram was drawn using ggplot2 in the R-language, and the KEGG database was used to analyze the functions and metabolic pathways of metabolites between the control, HFD and HFD + A groups. Novogene provides 16S rRNA sequencing and metabolomics services.

Correlation Analysis

P-values and rho between intestinal microbiome and fecal metabolites were determined using the Spearman statistical method. P < 0.05 and an absolute value of rho ≥ 0.8 were considered statistically significant between the Control group and HFD group.

Results

Atorvastatin Calcium Trihydrate Can Improve Disorders Caused by HFD

Figure 1A shows a diagram of the animal experimental plan. After a high-fat diet for three weeks, TC, TG, and LDL-C levels significantly different between the HFD and control groups (p < 0.05), and TC and TG were significantly different...
between the HFD + A and control groups (Figure S1), implying that the model was successful. The level of TC, TG, LDL-C and ALT in serum of HFD group induced by high-fat diet were significantly different from the control group (p < 0.05) (Figure 1B). The liver-to-body weight ratio increased significantly (p < 0.05) (Figure 1C). HE staining revealed obvious steatosis in the hepatocytes (Figure 1D). After five weeks of drug treatment, the levels of TC, TG, and LDL-C significantly reduced in the experimental rats as compared to the HFD group (p < 0.05) (Figure 1B), as well as the ratio of liver-to-body weight (p < 0.05) (Figure 1C), and the pathological changes in the liver significantly improved (Figure 1D). This shows that a HFD significantly increases blood lipid levels and causes liver steatosis. Moreover, atorvastatin calcium trihydrate significantly reduced blood lipid levels and improved liver steatosis.

Quality control results revealed that the data were reliable. We compared the three groups to initially illustrate the effect of HFD and atorvastatin on the intestinal microbiome (Figure 2). We employed the LEfSe analysis and set LDA to 4 to identify potential biomarkers of intestinal microbiome in all groups (Figure 2A). Figure 2B illustrates the PCA of the three groups, indicating that the community composition of the HFD group was significantly different from that of the control group, while the HFD+A group had a tendency to return to normal after atorvastatin treatment.

The Effect of HFD on Intestinal Microbiome and Metabolomics

We used LEfSe analysis to identify potential biomarkers of the intestinal microbiome in the HFD and control groups, with an LDA threshold of 4 (Figure 3A). IPATH (Figure 3B) showed that changes in the intestinal microbiome caused by an HFD affects metabolic pathways. We then used class-targeted metabolomics to study the changes in fecal and plasma metabolites. On this basis, we analyzed the correlation between nine intestinal microbiota markers at the genus level and 24 fecal metabolites involved in the KEGG pathway of the model and control groups. We observed that the intestinal microbiota has a strong correlation with the fecal metabolic pathway (Figure 3C). The intestinal microbiome that had the greatest impact on fecal metabolites included Alloprevotella, Collinsella, and Romboutsia. HFD may affect fecal metabolism by affecting Alloprevotella, Collinsella and Romboutsia. The level of some fecal metabolites changed in the model group than the control group (Figure 3D); 20 fecal metabolites increased, and 87 fecal metabolites decreased in the HFD group (Table S1). The KEGG bubble chart (Figure 3D) shows the top 20 metabolic pathways involved in different metabolites. “Propanoate metabolism” and “glycine, serine and threonine metabolism” were enriched. HFD reduces 2-hydroxybutyric acid involved

![Figure 2](https://doi.org/10.2147/DDDT.S379335)

**Figure 2** HFD alter the taxonomic composition of intestinal microbiome in Wistar rats, and atorvastatin can partially restore the intestinal microbiome changed with HFD. (A) LEfSe analysis of cladogram in three groups. The circle represents the classification level from phylum to genus. The diameter of the small circle is proportional to the relative abundance. (B) PCA Plot. The abscissa represents the first principal component (PC1), the ordinate represents the second principal component (PC2). The percentage represents the contribution value of PC1 or PC2 to the sample difference.

**Abbreviations:** HFD, high fat diet; HFD+A, high fat diet and atorvastatin calcium trihydrate.
in “propanoate metabolism” in fecal metabolomics, as well as ectoine, sarcosine, and betaine, which are involved in “glycine, serine and threonine metabolism” (Table S1). Some plasma metabolites equally changed (Figure 3E); 4 plasma metabolites were higher in the HFD group, and 61 plasma metabolites were lesser in the same group (Table S2). Figure 3E shows a KEGG bubble chart. The bubble chart of plasma metabolomics was not enriched for “glycine, serine and threonine metabolism”, but for “pantothenate and CoA biosynthesis” associated with this metabolism. HFD decreases 2-hydroxybutyric acid involved in
Atorvastatin Calcium Trihydrate Can Improve Intestinal Microbiome and Metabolic Disorders Caused by HFD

Through 16S rRNA sequencing and metabolomic analysis, we compared the potential biomarkers of intestinal microbiome and differential metabolites in feces and plasma from the HFD + A and HFD groups to determine the mechanism of action of atorvastatin calcium trihydrate. Figure 4A shows the cladogram for the LEfSe analysis, with the LDA threshold set at 3. Among them, Bacteroides were potential biomarkers in the HFD + A group. Compared with the model

![Diagram](image-url)

Figure 4 Atorvastatin calcium trihydrate improved intestinal microbiome and metabolic profiles disorders in rats’ feces and plasma induced by high fat diet. (A) LEfSe analysis of cladogram in HFD group and HFD+A group with LDA Score larger than 3. (B1) The volcano map of fecal metabolites between the HFD+A group and HFD group. (B2) KEGG bubble map of fecal metabolomics between the HFD+A group and HFD group. (C1) The volcano map of plasma metabolites between the HFD+A group and HFD group. (C2) KEGG bubble map of plasma Metabolomics.

---

“propanoate metabolism” in plasma metabolomics, 3-methyl-2-oxobutanoic acid and L-valine involved in “pantothenate and CoA biosynthesis” (Table S2). The synthesis of L-valine involved in “valine, leucine and isoleucine biosynthesis” were also enriched.
group, some fecal metabolites differed in the HFD+A group (Figure 4B1); 14 fecal metabolites in the HFD+A group were higher than those in the HFD group (Table S3), and Figure 4B2 shows a KEGG bubble chart related to metabolic pathways. 2-Hydroxybutyric acid is an increased differential metabolite related to “propanoate metabolism”, and ectoine is involved in “glycine, serine and threonine metabolism” (Table S3). Some plasma metabolites varied in the drug group (Figure 4C1); 61 plasma metabolites in the HFD+A group were higher than those in the HFD group, and 7 were lower than those in the HFD group (Table S4). The KEGG bubble chart shows the top 20 metabolic pathways in which different metabolites were involved (Figure 4C2). The increased 2-Hydroxybutyric acid in the plasma is involved in “propanoate metabolism”, and L-threonine and hydroxypyruvic acid are involved in “glycine, serine, and threonine metabolism” (Table S4). In addition, atorvastatin calcium trihydrate also affects the “pantothenate and CoA biosynthesis”, and “valine, leucine and isoleucine biosynthesis” in the plasma, as well as make L-valine involved in the two metabolic pathways cited above (Table S4). The metabolic pathways involved are shown in Figure 5.

**Discussion**
Consistent with previous findings, HFD raised blood lipids and caused liver steatosis in an animal model. Atorvastatin calcium trihydrate had a significant effect on lowering blood lipid levels and can reduce liver fat deformation. We investigated changes in the intestinal microbiome using 16s rRNA sequencing. We observed that an HFD has the potential to alter the structure and relative abundance of intestinal microbiome. The intestinal microbiome has a tendency to return to normal after treatment with atorvastatin calcium trihydrate. This reveals that HFD and the mechanism of action of atorvastatin are associated with intestinal microbiome.

Our findings also demonstrate a substantial relationship between intestinal microbiome and fecal metabolomics. We screened three intestinal microbiome that had the greatest impact on fecal metabolism under an HFD at the genus level,
namely *Alloprevotella, Collinsella*, and *Romboutsia*.

*Collinsella* can oxidize bile acids,\(^{34,35}\) thereby increasing cholesterol levels.\(^{36}\) *Alloprevotella* plays a therapeutic role in inflammatory diseases\(^{37}\) by producing short-chain fatty acids (SCFA).\(^{38}\) *Romboutsia* is associated with weight loss.\(^{39}\)

Therefore, *Romboutsia* is a potential biomarker for forecasting obesity. Alterations in *Alloprevotella* *Collinsella*, and *Romboutsia* may be gut triggers of fecal metabolic disturbances caused by an HFD.

In our study, HFD affected “propanoate metabolism” and “glycine, serine and threonine metabolism” in the fecal metabolome; “propanoate metabolism”, “valine, leucine and isoleucine biosynthesis”, and “pantothenate and CoA biosynthesis” in the plasma metabolome. HFD reduces 2-hydroxybutyric acid involved in “propanoate metabolism” in feces and plasma,\(^{21}\) and 2-hydroxybutyric acid is related to diabetes.\(^{40}\) Moreover, a metabolic disorder of 2-hydroxybutyric acid reflects that of propanoate,\(^{41}\) and “propanoate metabolism” is essential in the tricarboxylic acid cycle. Propanoate metabolic disorders can affect energy production.\(^{23}\) Moreover, our findings indicate that an HFD decreases 2-hydroxybutyric acid, thereby influencing propanoate metabolism, lipid metabolism and the citric acid cycle. Glycine, which is involved in the “glycine, serine and threonine metabolism”, is effective in reducing obesity and significantly affects lipid metabolism.\(^{24}\) Studies have shown that glycine and serine possible analogues for predicting and treating obesity.\(^{42}\) In addition, the glycine, serine and threonine metabolic pathways provide important energy metabolic precursors for entering the citric acid cycle. Our findings indicate that ectoine, sarcosine, and betaine are involved in “glycine, serine, and threonine metabolism”. Betaine is a methyl donor that is involved in single-carbon metabolism and plays a vital role in methylation. Betaine promotes obesity and insulin resistance thereby causing metabolic disorders.\(^{43}\) Thus, HFD affects “glycine, serine and threonine metabolism”, and consequently, lipid and energy metabolism. “Pantothenate and CoA biosynthesis” is related to “propanoate metabolism”. “Glycine, serine and threonine metabolism” through pyruvate can enter the tricarboxylic acid cycle through acetyl-CoA, which can be further degraded into coenzyme A. Our results illustrate that HFD affects “pantothenate and CoA biosynthesis”. Valine reduces the accumulation of lipids and alter lipid metabolism.\(^{44}\) HFD results in a decrease in of L-valine concentrations, which is involved in “pantothenate and CoA biosynthesis”. HFD affects “propanoate metabolism” in feces and plasma, which indicates that HFD may affect fecal metabolism through intestinal disturbance, and may also affect plasma metabolism, then increase blood lipid levels.

In summary, HFD alters the composition of the intestinal microbiome, such as *Alloprevotella, Collinsella*, and *Romboutsia* resulting in abnormal “propanoate metabolism” and “glycine, serine and threonine metabolism” in feces. In our study, there was a strong correlation between fecal and plasma metabolite levels. HFD alter the “propanoate metabolism”, “pantothenate and CoA biosynthesis”, and “valine, leucine and isoleucine biosynthesis” in plasma. This in turn plays a vital role in raising blood lipids and causing liver steatosis in rats.

When the LDA threshold was set to 3, *Bacteroides* were identified as potential biomarkers of the HFD+A group. *Bacteroides* are potential targets for the improvement of atorvastatin-induced fecal metabolism. *Bacteroides* belongs to the family *Bacteroidaceae*. *Bacteroidaceae* have anti-inflammatory effects and maintain intestinal barrier function.\(^{45}\) *Bacteroides* maintains the intestinal microecological balance,\(^{46,47}\) provide energy to the host, and prevent obesity.\(^{48}\) In addition, *Bacteroides* have bile salt hydrolase activity, and can improve cholesterol metabolism,\(^{16,17}\) thereby playing an important role in hyperlipidemia.\(^{19}\) *Bacteroides* can produce SCFA, and SCFA may play a key role in the improvement of hyperlipidemia metabolism.\(^{49}\)

In this study, we discovered that atorvastatin calcium trihydrate can improve “propanoate metabolism” as well as “glycine, serine and threonine metabolism” in the feces and plasma, and can also improve “pantothenate and CoA biosynthesis” and “valine, leucine and isoleucine biosynthesis” in plasma. Atorvastatin calcium trihydrate therapy increases 2-hydroxybutyric acid, a metabolite of propanoate, in plasma and feces. This demonstrates that the drug improves “propanoate metabolism”, thereby promoting fat oxidation and energy metabolism, reducing insulin resistance, lowering blood lipids, and reducing obesity. Atorvastatin calcium trihydrate therapy significantly increased ectoine (fecal metabolite), L-threonine (plasma metabolite), and hydroxypyruvic acid, correlating with “glycine, serine and threonine metabolism”. This means that the drug improves “glycine, serine and threonine metabolism” induced by an HFD, thereby reducing liver fat and plasma cholesterol. In addition, atorvastatin calcium trihydrate significantly increases L-valine, which is involved in “pantothenate and CoA biosynthesis” and “valine, leucine and isoleucine biosynthesis”. Pantothenate and CoA production are critical for fatty acid metabolism and the citric acid cycle. Increased intake of branched-chain amino acids has been shown to promote weight loss\(^{50}\) and considerably improves hepatic steatosis.\(^{51}\)
Moreover, valine decreases triglyceride levels and alters lipid metabolism.\textsuperscript{44} L-valine levels significantly increased following atorvastatin calcium trihydrate therapy, indicating that the drug enhanced lipid metabolism.

In summary, atorvastatin calcium trihydrate improves the composition of the intestinal microbiome, such as \textit{Bacteroides}, thereby affecting “propanoate metabolism” and “glycine, serine and threonine metabolism” in feces. On this basis, it affects “propanoate metabolism”, “glycine, serine and threonine metabolism”, “pantothenate and CoA biosynthesis”, and “valine, leucine and isoleucine biosynthesis” in plasma. Thus, it lowers blood lipid levels and liver steatosis in rats.

Our study also has limitations, we cannot yet rule out the potential effects of unidentified confounders, nor can we infer causality from the observed associations. Although we speculate that atorvastatin improves the lipid metabolism disorder induced by HFD in rats by inhibiting the reduction of \textit{Bacteroides}, the in-depth mechanism by requires further studies for confirmation.

**Conclusion**
Our study further demonstrated the lipid-lowering mechanism of atorvastatin from a multi-omics perspective. HFD and atorvastatin work through the intestinal microbiome and metabolic profiles; thus, altering the relative abundance of specific intestinal microbiome and associated metabolites through gut microbial manipulations could be considered as effective strategies for improving dyslipidemia.

**Abbreviations**
A, Atorvastatin calcium trihydrate; ALT, Alanine transaminase; AST, Aspartate transaminase; CTAB, Cetyl trimethylammonium bromide; FC, Foldchange; HDL-C, High-density lipoprotein cholesterol; HE, Hematoxylin-eosin; HFD, High-fat diet; LDL-C, Low-density lipoprotein cholesterol; LEfSe, Linear discriminant analysis effect size; MHC II, Major histocompatibility complex II; PCA, Principal component analysis; SCFA, Short-chain fatty acids; TC, Total cholesterol; TG, Triglyceride; VIP, Variable importance in the projection.

**Acknowledgments**
The authors want to thank Translational Medicine Core Facility of Shandong University for consultation and instrument availability that supported this work.

**Author Contributions**
All authors made a significant contribution to the work reported, whether that is in the conception, study design, execution, acquisition of data, analysis and interpretation, or in all these areas; took part in drafting, revising or critically reviewing the article; gave final approval of the version to be published; have agreed on the journal to which the article has been submitted; and agree to be accountable for all aspects of the work.

**Funding**
This study was supported by the Program for Changjiang Scholars and Innovative Research Team in University (IRT_17R68) and General Project of Shandong Natural Science Foundation, ZR2021MC166.

**Disclosure**
The authors declare that the research was conducted in the absence of any commercial or financial relationships that could be construed as a potential conflict of interest.

**References**
1. Hedayatnia M, Asadi Z, Zare-Feyzabadi R, et al. Dyslipidemia and cardiovascular disease risk among the MASHAD study population. \textit{Lipids Health Dis.} 2020;19(1):42. doi:10.1186/s12944-020-01204-y
2. Carlin JL, Grissom N, Ying Z, et al. Voluntary exercise blocks Western diet-induced gene expression of the chemokines CXCL10 and CCL2 in the prefrontal cortex. \textit{Brain Behav Immun.} 2016;58:82–90. doi:10.1016/j.bbi.2016.07.161
3. Lapergue B, Mohammad A, Shuaib A. Endothelial progenitor cells and cerebrovascular diseases. \textit{Prog Neurobiol.} 2007;83(6):349–362. doi:10.1016/j.pneurobio.2007.08.001
4. Henk HJ, Paoli CJ, Gandra SR. A retrospective study to examine healthcare costs related to cardiovascular events in individuals with hyperlipidemia. *Adv Ther.* 2015;32(11):1104–1116. doi:10.1007/s12325-015-0264-7

5. An HJ, Kim JY, Gwon MG, et al. Beneficial effects of SREBP decoy oligodeoxynucleotide in an animal model of hyperlipidemia. *Int J Mol Sci.* 2020;21(2):552. doi:10.3390/ijms21020552

6. Okada Y, Yamaguchi K, Nakajima T, et al. Rosuvastatin ameliorates high-fat and high-cholesterol diet-induced nonalcoholic steatohepatitis in rats. *Liver Int.* 2013;33(2):301–311. doi:10.1111/lci.12033

7. Tavares TB, Santos IB, de Bem GF, et al. Therapeutic effects of açai seed extract on hepatic steatosis in high-fat diet-induced obesity in male mice: a comparative effect with rosuvastatin. *J Pharm Pharmacol.* 2020;72(12):1921–1932. doi:10.1111/jphp.13356

8. Khan TJ, Ahmed YM, Zamzami MA, et al. Effect of atorvastatin on the gut microbiota of high fat diet-induced hypercholesterolemic rats. *Sci Rep.* 2018;8(1):662. doi:10.1038/s41598-017-19013-2

9. Sharma M, Mehta I. Surface stabilized atorvastatin nanocrystals with improved bioavailability, safety and antihyperlipidemic potential. *Sci Rep.* 2019;9(1):16105. doi:10.1038/s41598-019-52645-0

10. Daniel H, Gholami AM, Berry D, et al. High-fat diet alters gut microbiota physiology in mice. *ISME J.* 2014;8(2):295–308. doi:10.1038/ismej.2013.155

11. Liu L, Zhang D, Zhu H, et al. Berberine treatment increases Akkermansia in the gut and improves high-fat diet-induced atherosclerosis in Apoe(−/−) mice. *Atherosclerosis.* 2018;268:117–126. doi:10.1016/j.atherosclerosis.2017.11.023

12. Araújo JR, Tomás J, Brenner C, et al. Impact of high-fat diet on the intestinal microbiota and small intestinal physiology before and after the onset of obesity. *Biochimie.* 2017;141:97–106. doi:10.1016/j.bioch.2017.05.019

13. Khan TJ, Ahmed YM, Zamzami MA, et al. Atorvastatin treatment modulates the gut microbiota of the hypercholesterolemic patients. *OMICS.* 2018;22(2):154–163. doi:10.1089/omi.2017.0130

14. Schüeler M, Caeser R. Dietary lipids, gut microbiota and lipid metabolism. *Rev Endocr Metab Disord.* 2019;20(4):461–472. doi:10.1007/s1154-019-09512-0

15. Gerard P, Lepèrcq P, Leclerc M, et al. Bacteroides sp. Strain D8, the first cholesterol-reducing bacterium isolated from human feces. *Redox Biol.* 2020;10:1947. doi:10.3389/fmicb.2019.01947

16. Wahlström A, Sayin SI, Marschall H-U, et al. Intestinal crosstalk between bile acids and microbiota and its impact on host metabolism. *Cell Metab.* 2016;24(1):41–50. doi:10.1016/j.cmet.2015.06.005

17. Ridlon JM, Kang D-J, Hylemon PB. Bile salt biotransformations by human intestinal bacteria. *J Lipid Res.* 2006;47(2):241–259. doi:10.1194/jlr.R500013-JLR200

18. Kim J, Lee H, An J, et al. Alterations in gut microbiota by statin therapy and possible intermediate effects on hyperglycemia and hyperlipidemia. *Front Microbiol.* 2019;10:1947. doi:10.3389/fmicb.2019.01947

19. Henk HJ, Paoli CJ, Gandra SR. A retrospective study to examine healthcare costs related to cardiovascular events in individuals with hyperlipidemia. *Adv Ther.* 2015;32(11):1104–1116. doi:10.1007/s12325-015-0264-7

20. Van Y, Wang FL, Yuan JH, et al. Effects of dietary fat on gut microbiota and faecal metabolites, and their relationship with cardiometabolic risk factors: a 6-month randomised controlled-feeding trial. *Gut.* 2019;68(8):1417–1429. doi:10.1136/gutjnl-2018-317609

21. Xu Y, Han J, Dong J, et al. Metabolomics characterizes the effects and mechanisms of quercetin in nonalcoholic fatty liver disease. *Int J Mol Sci.* 2019;20(5):2220. doi:10.3390/ijms20052220

22. Edgar RC, Haas BJ, Clemente JC, et al. UCHIME improves sensitivity and speed of chimera detection. *Bioinformatics.* 2011;27(16):2194–2200. doi:10.1093/bioinformatics/btr181

23. Dong Y, Svingen GF, Pedersen ER, et al. Plasma glycine and risk of acute myocardial infarction in patients with suspected stable angina pectoris. *J Am Heart Assoc.* 2015;4(5):e002621. doi:10.1161/JAHA.115.002621

24. Bokulich NA, Subramanian S, Faith JJ, et al. Quality-filtering vastly improves diversity estimates from Illumina amplicon sequencing. *Nat Methods.* 2013;10(1):57–59. doi:10.1038/nmeth.2276

25. Chen HH, Tseng YJ, Wang SY, et al. The metabolome profiling and pathway analysis in metabolic healthy and abnormal obesity. *Int J Obes.* 2015;39(8):1241–1248. doi:10.1038/ijo.2015.65

26. Han JS, Kim K, Jung Y, et al. Metabolic alterations associated with atorvastatin/fenofibric acid combination in patients with atherogenic dyslipidaemia: a randomized controlled trial for comparison with escalated-dose atorvastatin. *Sci Rep.* 2018;8(1):14642. doi:10.1038/s41598-018-33058-x

27. Kobulnik NA, Subramanian S, Faith JJ, et al. Quality-filtering vastly improves diversity estimates from Illumina amplicon sequencing. *Nat Methods.* 2013;10(1):57–59. doi:10.1038/nmeth.2276

28. Haas BJ, Gevers D, Earl AM, et al. Chimera 16S rRNA sequence formation and detection in Sanger and 454-pyrosequenced PCR amplicons. *Genome Res.* 2011;21(3):494–504. doi:10.1101/gr.112730.110

29. Edgar RC, Haas BJ, Clemente JC, et al. UCHIME improves sensitivity and speed of chimera detection. *Bioinformatics.* 2011;27(16):2194–2200. doi:10.1093/bioinformatics/btr181

30. Gustafson ES, Kasper F, Schüeler M, et al. Novel SILVA ribosomal RNA gene database project: improved data processing and web-based tools. *Nucleic Acids Res.* 2013;41:D590–D596. doi:10.1093/nar/gks1219

31. Luo P, Dai W, Yin P, et al. Multiple reaction monitoring-ion pair finder: a systematic approach to transform nontargeted mode to pseudotargeted mode for metabolomics study based on liquid chromatography-mass spectrometry. *Anal Chem.* 2015;87(10):5050–5055. doi:10.1021/acs.analchem.5b00615

32. Gao Y, Zhang W, Zeng LQ, et al. Exercise and dietary intervention ameliorate high-fat diet-induced NAFLD and liver aging by inducing lipophagy. *Redox Biol.* 2020;36:101635. doi:10.1016/j.redox.2020.101635

33. Frost F, Storck LJ, Kacprzowski T, et al. A structured weight loss program increases gut microbiota phylogenetic diversity and reduces levels of Collinsella in obese type 2 diabetics: a pilot study. *PLoS One.* 2019;14(7):e0219489. doi:10.1371/journal.pone.0219489

34. Asbury S, Atallah E, Vijay A, et al. Lower gut microbiome diversity and higher abundance of proinflammatory genus Collinsella are associated with biopsy-proven nonalcoholic steatohepatitis. *Gut Microbes.* 2020;11(3):569–580. doi:10.1080/19490076.2019.1681186

35. Gomez-Arango LF, Barrett HL, Wilkinson SA, et al. Low dietary fiber intake increases Collinsella abundance in the gut microbiota of overweight and obese pregnant women. *Gut Microbes.* 2018;9(3):189–201. doi:10.1080/19490076.2017.1406584
37. Richards JL, Yap YA, McLeod KH, et al. Dietary metabolites and the gut microbiota: an alternative approach to control inflammatory and autoimmune diseases. Clin Transl Immunol. 2016;5(5):e82. doi:10.1038/cti.2016.29
38. Zhou LY, Xiao XH, Li M, et al. Maternal exercise improves high-fat diet-induced metabolic abnormalities and gut microbiota profiles in mouse dams and offspring. Front Cell Infect Microbiol. 2020;10:292. doi:10.3389/fcimb.2020.00292
39. Liu J, Yue S, Yang Z, et al. Oral hydroxysafflor yellow A reduces obesity in mice by modulating the gut microbiota and serum metabolism. Pharmacol Res. 2018;134:40–50. doi:10.1016/j.phrs.2018.05.012
40. Taalberg E, Kilk K. Mapping metabolite and ICD-10 associations. Metabolites. 2020;10(5):196. doi:10.3390/metabo10050196
41. Grimaldi M, Palisi A, Marino C, et al. NMR-based metabolomic profile of hypercholesterolemic human sera: relationship with in vitro gene expression? PLoS One. 2020;15(4)e0231506. doi:10.1371/journal.pone.0231506
42. Zhuang T, Liu X, Wang W, et al. Dose-related urinary metabolic alterations of a combination of quercetin and resveratrol-treated high-fat diet fed rats. Front Pharmacol. 2021;12:655563. doi:10.3389/fphar.2021.655563
43. Wang J, Wu Z, Li D, et al. Nutrition, epigenetics, and metabolic syndrome. Antioxid Redox Signal. 2012;17(2):282–301. doi:10.1089/ars.2011.4381
44. Cojocaru E, Magdalena Leon-Constantin M, Ungureanu C, et al. Hypolipemiants actions and possible cardioprotective effects of valine and leucine: an experimental study. Medicina. 2021;57(3):239. doi:10.3390/medicina57030239
45. O’Connor K, Morrissette M, Strandwitz P, et al. Cranberry extracts promote growth of Bacteroidaceae and decrease abundance of Enterobacteriaceae in a human gut simulator model. PLoS One. 2019;14(11):e0224836. doi:10.1371/journal.pone.0224836
46. Han J, Zhang R, Muheyati D, et al. The effect of chickpea dietary fiber on lipid metabolism and gut microbiota in high-fat diet-induced hyperlipidemia in rats. J Med Food. 2021;24(2):124–134. doi:10.1089/jmf.2020.4800
47. Sears CL. A dynamic partnership: celebrating our gut flora. Anaerobe. 2005;11(5):247–251. doi:10.1016/j.anaerobe.2005.05.001
48. Wexler HM. Bacteroides: the good, the bad, and the nitty-gritty. Clin Microbiol Rev. 2007;20(4):593–621. doi:10.1128/CMR.00008-07
49. Zhang X, Coker OO, Chu ES, et al. Dietary cholesterol drives fatty liver-associated liver cancer by modulating gut microbiota and metabolites. Gut. 2021;70(4):761–774. doi:10.1136/gutjnl-2019-319664
50. Zhang F, Zhao S, Yan W, et al. Branched chain amino acids cause liver injury in obese/diabetic mice by promoting adipocyte lipolysis and inhibiting hepatic autophagy. EBiomedicine. 2016;13:157–167. doi:10.1016/j.ebiom.2016.10.013
51. Takegoshi K, Honda M, Okada H, et al. Branched-chain amino acids prevent hepatic fibrosis and development of hepatocellular carcinoma in a non-alcoholic steatohepatitis mouse model. Oncotarget. 2017;8(11):18191–18205. doi:10.18632/oncotarget.15304